Viking Therapeutics presents obesity drug trial results at conference

May 12, 2026 7:05 AM

Viking Therapeutics Inc. (NASDAQ: VKTX) presented data from its 13-week Phase 2 trial of oral VK2735 at the European Congress ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found